Inclisiran

[anonymous]

Novartis shits the bed again

 

[anonymous]

CRL for unresolved facility inspection related conditions? Who is getting fired over this? What a complete shit show. Novartis never fails to disappoint.

 

[anonymous]

No inspection was conducted and the FDA will establish a path to do one.

But....they won’t do this until it is deemed safe to travel to the site. What does this mean? Airports are far from empty these days. What is really going on?

The whole thing seems skeptical but one thing is certain.....the Covid conditions that have been so recently ignored/overlooked will now dictate a big delay. Wonderful.

 

[anonymous]

They asked for a slow roll-out, they got it

 

[anonymous]

What are we talking here-days, weeks, months?

 

[anonymous]

A CRL usually takes 6 months up to 18 months to resolve. The FDA has other problems now, Novartis is on the back burner.

 

[anonymous]

Stupid Novartis fucks up again. Inclisiran price just got increased, these greedy bastards will get their money back

 

[anonymous]

Stupid Novartis fucks up again. Inclisiran price just got increased, these greedy bastards will get their money back

For shame. How dare they look to make a profit on an investment. I'm with you. I, usually, sell my stocks and home for 1/4 of what I paid. It makes my heart fill with gold.

 

[anonymous]

Who cares what the price is if they can’t get it approved.

 

[anonymous]

Will be fun listening to the spin on the townhall.

 

[anonymous]

Is anyone surprised at this point? Mike & Duane are tick- tocking and acting like the pandemic is over. SOC lead launch teams are a mess and accounts are based on opinions of people who don’t have a definable job.

 

[anonymous]

Is anyone surprised at this point? Mike & Duane are tick- tocking and acting like the pandemic is over. SOC lead launch teams are a mess and accounts are based on opinions of people who don’t have a definable job.

Nope, not surprised. None of these over-paid asshole have any buy and bill experience. They paid twice what the drug is even worth. The whole class has been out for 5 years and not one had sold anywhere close to a billion. Inclisiran looks less effective than the others and not as clean. Total shit show.

 

[anonymous]

Total shit show.

Yup. That be Novartis. They need to change the symbol into the emjoi smiling turd pile.

Better yet, license Mr Hanley from Cartoon ,or who ever owns SP.

 

[anonymous]

Are the AdSoCs earning their sweet paycheck reaching out to all their Suite C contacts to put the necessary steps in place?

 

[anonymous]

Leadership on this product is a joke. This launch will flop. Who has heard of a market access launch? Compliance issues

 

[anonymous]

Nope, not surprised. None of these over-paid asshole have any buy and bill experience. They paid twice what the drug is even worth. The whole class has been out for 5 years and not one had sold anywhere close to a billion. Inclisiran looks less effective than the others and not as clean. Total shit show.

Let’s be honest, it really depends to a good degree on how it is priced. No matter what, the class will always face PA/step edit hurdles as statins plus generic zeta can provide comparable efficacy. So it’s really not going to be first line, however it could own the class (and expand it) IF it’s priced very aggressively. I’m not sure exactly what the number is, but maybe $2-3kyr before rebates would open the floodgates. There is a lot of positive anticipation from the cardio folks, so we will see.

 

[anonymous]

Let’s be honest, it really depends to a good degree on how it is priced. No matter what, the class will always face PA/step edit hurdles as statins plus generic zeta can provide comparable efficacy. So it’s really not going to be first line, however it could own the class (and expand it) IF it’s priced very aggressively. I’m not sure exactly what the number is, but maybe $2-3kyr before rebates would open the floodgates. There is a lot of positive anticipation from the cardio folks, so we will see.

2-3k a year is out of touch with reality. It’s going to be premium priced, have zero outcomes and reps who don’t have buy/bill experience. Launch will be a disaster if it’s ever actually approved.

 

[anonymous]

2-3k a year is out of touch with reality. It’s going to be premium priced, have zero outcomes and reps who don’t have buy/bill experience. Launch will be a disaster if it’s ever actually approved.

All true. Direction from the top indicates even leadership doesn’t understand the buy and bill process.

 

[anonymous]

You are 1000% correct. A market access launch is a joke. Leadership is from sales. Get some people in here who understand buy and bill.
Big compliance issues going on.

 

[anonymous]

You are 1000% correct. A market access launch is a joke. Leadership is from sales. Get some people in here who understand buy and bill.
Big compliance issues going on.

We F everything up. Everything. The only thing Novartis is good at is making every single task as difficult as possible.